Remove Bicuspid/Mitral Remove Heart Valves Remove Quality of Life
article thumbnail

Novel Tricuspid Valve Procedure Improves Patients' Quality of Life and Health Status

DAIC

Blood then flows backwards within the heart and may cause symptoms such as shortness of breath and swelling in the abdomen, legs or veins in the neck.

Tricuspid 105
article thumbnail

AHA Raises Awareness on HVD

DAIC

22, 2025More than 60,000 people die from heart valve disease (HVD) in the U.S. each year, according to the American Heart Association 2025 Heart Disease and Stroke Statistical Update. This year on Heart Valve Disease Awareness Day (Feb. tim.hodson Tue, 03/04/2025 - 14:11 Feb.

article thumbnail

Henry Ford Health Cardiologists Publish Case Series Study on Heart Valve Procedure

DAIC

These key takeaways from the research letter on IVL-facilitated valvuloplasty for severely calcified mitral valve stenosis are published in the Journal of the American College of Cardiology (JACC) Cardiovascular Interventions. an interventional cardiologist and structural heart disease expert at Henry Ford Health. “We

article thumbnail

Atrium Health Sanger Heart & Vascular Institute Performs Landmark Heart Valve Surgery

DAIC

Tricuspid regurgitation is a condition where the tricuspid valve, located between the right atrium and right ventricle of the heart, fails to close properly, allowing blood to flow backward. This can lead to symptoms such as severe shortness of breath, swelling in the legs and abdomen and a significant reduction in quality of life.

article thumbnail

Abbott Announces FDA Approval of First-of-its-kind Device to Repair Leaky Tricuspid Heart Valve, TriClip

DAIC

Food and Drug Administration (FDA) approval of its TriClip, a first-of-its-kind device to repair leaky tricuspid heart valve, for which more than 1.6 are affected by tricuspid regurgitation, 1 which can severely impact quality of life. Abbott has announced U.S million people in the U.S. are estimated to be affected.

Tricuspid 105
article thumbnail

FDA Advisory Committee Votes in Favor of Abbott’s First-of-its-kind Triclip System to Treat People with a Leaky Tricuspid Heart Valve

DAIC

The panel's vote will be considered by the FDA when making a decision regarding the approval of TriClip, a first-of-its-kind minimally invasive device specifically designed to treat the difficult-to-access tricuspid valve. chief medical officer and divisional vice president of medical affairs of Abbott's structural heart business.

Tricuspid 102
article thumbnail

Taskforce Develops New Standards to Monitor Adults with Heart Valve Disease

DAIC

Highlights include: Due to the aging population and improvement in diagnostic strategies, the prevalence of heart valve disease is expected to double by 2040 and triple by 2060.As As a result, it is estimated that the number of patients requiring heart valve interventions will increase significantly in the coming decades.